Lori A . Martell

Learn More
BACKGROUND Patients treated with clopidogrel who have ≥1 loss of function alleles for CYP2C19 have an increased risk for adverse cardiovascular events. In 2010, the US Food and Drug Administration issued a boxed warning cautioning against the use of clopidogrel in such patients. We sought to assess the impact of CYP2C19 genetic testing on prescribing(More)
HMG-CoA reductase inhibitors, commonly known as statins, are some of the most widely prescribed medications worldwide and have been shown to be effective at lowering cholesterol in numerous long-term prospective trials, yet there are significant limitations to their use. First, patients receiving statin therapy have relatively low levels of medication(More)
Clopidogrel, an irreversible ADP-receptor blocker, has been shown to reduce the risk of major adverse cardiovascular events in patients with an acute coronary syndrome (ACS) and those undergoing percutaneous coronary intervention (PCI). However, there is significant interindividual variability in the response to clopidogrel, and patients with higher levels(More)
  • 1